In this slide show we highlight some of the top news on gynecologic cancers in 2017, including studies on surgery for cervical and ovarian cancer, the FDA approval of niraparib, and more.
Rintatolimod Combo Yields Clinical Benefit in Recurrent Ovarian Cancer
Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.
Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer
The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.
Avutometinib Combo Yields Responses in Serous Ovarian Cancer Subgroups
Findings from the phase 2 RAMP 201 trial highlight responses with avutometinib/defactinib in those with KRAS-mutated low-grade serous ovarian cancer and other patient subgroups.
Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances
Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.
CRX100 Yields Responses, Tolerability in Platinum-Resistant Ovarian Cancer
Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.
Frontline Durvalumab Combo Improves PFS/DOR in Advanced Endometrial Cancer
Data from the DUO-E trial support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.